Estimated annual direct expenditures in the united states as a result of inappropriate hypertension treatment according to national treatment guidelines

Clinical Therapeutics

Volumn 31, Issue 7, 2009, Pages 1581-1594

  Balu, Sanjeev ^a  

^a ABT ASSOCIATES   (United States)

Author keywords

direct cost; guidelines; hypertension; JNC 7; treatment

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ARTICLE; COMORBIDITY; CONTROLLED STUDY; DRUG COST; HEALTH CARE COST; HEALTH CARE UTILIZATION; HYPERTENSION; PRACTICE GUIDELINE; PREVALENCE; UNITED STATES;

ADOLESCENT; ADULT; ANTIHYPERTENSIVE AGENTS; DATABASES, FACTUAL; FEMALE; GUIDELINE ADHERENCE; HEALTH EXPENDITURES; HUMANS; HYPERTENSION; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 68649090748     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.07.010     Document Type: Article

References (44)

1. Cherry D.K., and Woodwell D.A. National Ambulatory Medical Care Survey: 2000 Summary. Adv Data. 328 (2002) 1-32
2. Berlowitz D.R., Ash A.S., Hickey E.C., et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 339 (1998) 1957-1963
3. Chobanian A.V., Bakris J.L., Black H.R., the National Heart, Lung, Blood Institute Joint National Committee on Prevention, Detection, Evaluation, Treatment of High Blood Pressure, and National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report [published correction appears in JAMA. 2003;290:197]. JAMA 289 (2003) 2560-2572
4. Vasan R.S., Beiser A., Seshadri S., et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 287 (2002) 1003-1010
5. Cutler J.A., Sorlie P.D., Wolz M., et al. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension. 52 (2008) 818-827
6. Ostchega Y., Dillon C.F., Hughes J.P., et al. Trends in hypertension prevalence, awareness, treatment, and control in older US adults: Data from the National Health and Nutrition Examination Survey 1988 to 2004. J Am Geriatr Soc. 55 (2007) 1056-1065
7. Wang T.J., and Vasan R.S. Epidemiology of uncontrolled hypertension in the United States. Circulation. 112 (2005) 1651-1662
8. Gu Q., Burt V.L., Paulose-Ram R., and Dillon C.F. Gender differences in hypertension treatment, drug utilization patterns, and blood pressure control among US adults with hypertension: Data from the National Health and Nutrition Examination Survey 1999-2004. Am J Hypertens. 21 (2008) 789-798
9. Hajjar I., and Kotchen T.A. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 290 (2003) 199-206
10. Payne K.A., and Caro J.J. Evaluating the true cost of hypertension management: Evidence from actual practice. Exp Rev Pharmacoeconomics Outcomes Res. 4 (2004) 179-187
11. Druss B.G., Marcus S.C., Olfson M., et al. Comparing the national economic burden of five chronic conditions. Health Aff (Millwood). 20 (2001) 233-241
12. Hodgson T.A., and Cohen A.J. Medical care expenditures for selected circulatory diseases: Opportunities for reducing national health expenditures. Med Care. 37 (1999) 994-1012
13. Hodgson T.A., and Cai L. Medical care expenditures for hypertension, its complications, and its comorbidities. Med Care. 39 (2001) 599-615
14. Garis R.I., and Farmer K.C. Examining costs of chronic conditions in a Medicaid population. Manag Care. 11 (2002) 43-50
15. American Heart Association, American Stroke Association. Heart disease and stroke statistics: 2008 Update at-a-glance. http://www.americanheart.org/downloadable/heart/1200078608862HS_Stats%202008.final.pdf Accessed February 20, 2009.
16. Balu S., and Thomas III J. Incremental expenditure of treating hypertension in the United States. Am J Hypertens. 19 (2006) 810-816
17. Gu Q., Paulose-Ram R., Dillon C., and Burt V. Antihypertensive medication use among US adults with hypertension. Circulation. 113 (2006) 213-221
18. Milchak J.L., Carter B.L., Ardery G., et al., the Joint National Committee on Prevention, Detection, Evaluation, Treatment of High Blood Pressure. Physician adherence to blood pressure guidelines and its effect on seniors. Pharmacotherapy. 28 (2008) 843-851
19. Jami P., Smith P., Moningi S., et al. Compliance with Joint National Committee 7 guidelines in hypertension management in a teaching institution. Am J Med Qual. 22 (2007) 251-258
20. Ardery G., Carter B.L., Milchak J.L., et al. Explicit and implicit evaluation of physician adherence to hypertension guidelines. J Clin Hypertens (Greenwich). 9 (2007) 113-119
21. Medical Expenditure Panel Survey (MEPS). MEPS HC-099: 2006 Full year population characteristics (HC-099 replaced by HC-105). http://www.meps.ahrq.gov/mepsweb/data_stats/download_data_files_detail.jsp?cboPufNumber=HC-099 Accessed February 18, 2009
22. Mukhopadhyay P.K., An A.B., Tobias R.D., and Watts D.L. Try, try again: Replication-based variance estimation methods for survey data analysis in SAS 9.2. http://www2.sascom/proceedings/forum2008/367-2008.pdf Accessed February 16, 2009.
23. Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey. http://www.meps.ahrq.gov/mepsweb Accessed February 16, 2009
24. Brown L.J., Wall T.P., and Manski R.J. The funding of dental services among US adults aged 18 years and older: Recent trends in expenditures and sources of funding. J Am Dent Assoc. 133 (2002) 627-635
25. D'Hoore W., Bouckaert A., and Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative databases. J Clin Epidemiol. 49 (1996) 1429-1433
26. Duan N. Smearing estimate: A non-parametric retransformation method. J Am Stat Assoc. 78 (1983) 605-610
27. Howard G., Prineas R., Moy C., et al. Racial and geographic differences in awareness, treatment, and control of hypertension: The Reasons for Geographic and Racial Differences in Stroke study. Stroke. 37 (2006) 1171-1178
28. Wyatt S.B., Akylbekova E.L., Wofford M.R., et al. Prevalence, awareness, treatment, and control of hypertension in the Jackson Heart Study. Hypertension. 51 (2008) 650-656
29. Burt V.L., Whelton P., Roccella E.J., et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 25 (1995) 305-313
30. Wolf-Maier K., Cooper R.S., Banegas J.R., et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 289 (2003) 2363-2369
31. Xu K.T., Moloney M., and Phillips S. Economics of suboptimal drug use: Cost-savings of using JNC-recommended medications for management of uncomplicated essential hypertension. Am J Manag Care. 9 (2003) 529-536
32. Fischer M.A., and Avorn J. Economic implications of evidence-based prescribing for hypertension: Can better care cost less?. JAMA 291 (2004) 1850-1856
33. Pizzi L.T., Patel N.M., Maio V.M., et al. Economic implications of non-adherence to treatment recommendations for hemodialysis patients with anemia. Dial Transplant. 35 (2006) 660-671
34. Shibata M.C., Nilsson C., Hervas-Malo M., et al. Economic implications of treatment guidelines for congestive heart failure. Can J Cardiol. 21 (2005) 1301-1306
35. Muller A. Education, income inequality, and mortality: A multiple regression analysis. BMJ 324 (2002) 23-25
36. US Census Bureau. United States Census 2000. http://www.census.gov/main/www/cen2000.html Accessed January 29, 2009
37. Romano P.S., and Mark D.H. Bias in the coding of hospital discharge data and its implications for quality assessment. Med Care. 32 (1994) 81-90
38. Falkner B. Hypertension in children and adolescents: Epidemiology and natural history [published online ahead of print May 7, 2009]. Pediatr Nephrol. doi: 10.1007/s00467-009-1200-3.
39. Lepor H. The evolution of alpha-blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 8 Suppl 4 (2006) S3-S9
40. Saleh S.S., Szebenyi S., Carter J.A., et al. Patterns and associated health services costs of antihypertensive drug modifications. J Clin Hypertens (Greenwich). 10 (2008) 43-50
41. Neutel J.M., and Smith D.H. Improving patient compliance: A major goal in the management of hypertension. J Clin Hypertens (Greenwich). 5 (2003) 127-132
42. Munger M.A., Van Tassell B.W., and LaFleur J. Medication nonadherence: An unrecognized cardiovascular risk factor. MedGenMed. 9 (2007) 58
43. The High Concentration of US Health Care Expenditures. Rock-ville, Md: Agency for Healthcare Research and Quality; 2006. Research in Action issue 19, AHRQ Pub. No. 06-0060. http://www.ahrq.gov/research/ria19/expendria.pdf Accessed February 2, 3009
44. Jackson J.H., Sobolski J., Krienke R., et al. Blood pressure control and pharmacotherapy patterns in the United States before and after the release of the Joint National Comittee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) guidelines. J Am Board Fam Med. 21 (2008) 512-521